Treatment of chronic hepatitis C: What is new?

AASLD and IDSA guidelines 2014, EASL practice guidelines: management of hepatitis C virus infection, J Hepatol, 60, 392, 10.1016/j.jhep.2013.11.003 Omata, 2012, APASL consensus statements and management algorithms for hepatitis C virus infection, Hepatol Int, 6, 409, 10.1007/s12072-012-9342-y 2010, Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting, Dig Liver Dis, 42, 81, 10.1016/j.dld.2009.08.001 Bochud, 2009, Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C, J Hepatol, 51, 655, 10.1016/j.jhep.2009.05.016 Nkontchou, 2011, HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis, J Viral Hepat, 18, e516, 10.1111/j.1365-2893.2011.01441.x Bisceglie, 1990, A randomized, double-blind, placebo-controlled trial of recombinant human alpha-interferon therapy for chronic non-A, non-B (type C) hepatitis, J Hepatol, 11, S36, 10.1016/0168-8278(90)90161-J Reichard, 1991, Ribavirin treatment for chronic hepatitis C, Lancet, 337, 1058, 10.1016/0140-6736(91)91707-2 Manns, 2001, Pegin- terferon alpha-2b plus ribavirin compared with inter- feron alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial, Lancet, 358, 358, 10.1016/S0140-6736(01)06102-5 Lindsay, 2001, A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C, Hepatology, 34, 395, 10.1053/jhep.2001.26371 Schinazi, 2010, HCV drug discovery aimed at viral eradication, J Viral Hepat, 17, 77, 10.1111/j.1365-2893.2009.01246.x Trepo, 2014, A brief history of hepatitis milestones, Liver Int, 34, 29, 10.1111/liv.12409 Tovo, 2014, Chronic hepatitis C genotype 1 virus: who should wait for treatment?, World J Gastroenterol, 20, 2867, 10.3748/wjg.v20.i11.2867 Fried, 2002, Side effects of therapy of hepatitis C and their management, Hepatology, 36, S237, 10.1002/hep.1840360730 Manns, 2006, Treating viral hepatitis C: efficacy, side effects, and complications, Gut, 55, 1350, 10.1136/gut.2005.076646 Hézode, 2012, Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice, Liver Int, 32, 32, 10.1111/j.1478-3231.2011.02707.x Van der Meer, 2014, Is there sufficient evidence to recommend antiviral therapy in hepatitis C, J Hepatol, 60, 191, 10.1016/j.jhep.2013.07.043 van der Meer, 2012, Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis?, JAMA, 308, 2584, 10.1001/jama.2012.144878 Donnelly, 2010, Interferon-lambda: a new addition to an old family, J Interferon Cytokine Res, 30, 555, 10.1089/jir.2010.0078 2014, Transcriptional regulation of IFN-{lambda} genes in hepatitis C virus-infected hepatocytes via IRF-3.IRF-7.NF-kB complex, J Biol Chem, 289, 5310, 10.1074/jbc.M113.536102 Muir, 2012, Peginterferon lambda-1a (lambda) is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus (HCV) infection, compared to peginterferon alfa-2a (Alfa) Chatterji, 2014, Alisporivir plus NS5A inhibitor combination provides additive to synergistic anti-HCV activity without detectable cross resistance, Antimicrob Agents Chemother, 10.1128/AAC.00016-14 Flisiak, 2009, The cyclophilin inhibitor DEBIO-025 combined with PEG IFN-alpha2a significantly reduces viral load in treatment-naive hepatitis C patients, Hepatology, 49, 1460, 10.1002/hep.22835 Flisiak, 2011, Once-daily alisporivir (DEB025) plus peginterferon alfa-2a/ribavirin results in superior sustained virologic response in chronic hepatitis C genotype 1 treatment-naive patients, J Hepatol, 54, S2, 10.1016/S0168-8278(11)60006-8 Janssen, 2013, Treatment of HCV infection by targeting microRNA, N Engl J Med, 368, 1685, 10.1056/NEJMoa1209026 Asselah, 2014, Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir?, Liver Int, 34, 60, 10.1111/liv.12424 Lawitz, 2013, Sofosbuvir for previously untreated chronic hepatitis C infection, N Engl J Med, 368, 1878, 10.1056/NEJMoa1214853 Marcellin, 2014, Viral hepatitis: impressive advances but still a long way to eradication of the disease, Liver Int, 34, 1, 10.1111/liv.12422 Gane, 2010, Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial, Lancet, 376, 1467, 10.1016/S0140-6736(10)61384-0 Boccaccio, 2014, Management of HCV patients with cirrhosis with direct acting antivirals, Liver Int, 34, 38, 10.1111/liv.12391 Zeuzem, 2011, Efficacy of the protease inhibitor BI201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection, Gastroenterology, 141, 2047, 10.1053/j.gastro.2011.08.051 Kowdley, 2012, A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders with HCV genotype 1 infection, Hepatology, 56, LB1 Schinazi, 2014, HCV direct-acting antiviral agents: the best interferon-free combinations, Liver Int, 34, 69, 10.1111/liv.12423 Lok, 2012, Preliminary study of two antiviral agents for hepatitis C genotype 1, N Engl J Med, 366, 216, 10.1056/NEJMoa1104430 Lawitz, 2014, Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial, Lancet, 383, 515, 10.1016/S0140-6736(13)62121-2 Mohd Hanafiah, 2013, Global epidemiology of hepatitis C virus Infection: new estimates of age-specific antibody to HCV seroprevalence, Hepatology, 57, 1333, 10.1002/hep.26141 Shepard, 2005, Global epidemiology of hepatitis C virus infection, Lancet Infect Dis, 5, 558, 10.1016/S1473-3099(05)70216-4 1999, Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium, J Viral Hepat, 6, 35 Wasley, 2000, Epidemiology of hepatitis C: geographic differences and temporal trends, Semin Liver Dis, 20, 1, 10.1055/s-2000-9506 Sy, 2006, Epidemiology of hepatitis C virus (HCV) infection, Int J Med Sci, 3, 41, 10.7150/ijms.3.41 Alter, 2007, Epidemiology of hepatitis C virus infection, World J Gastroenterol, 13, 2436, 10.3748/wjg.v13.i17.2436 Yen, 2003, The epidemiology of hepatitis C virus infection, J Clin Gastroenterol, 36, 47, 10.1097/00004836-200301000-00015 Mukhopadhya, 2008, HCV in India, J Biosci, 33, 465, 10.1007/s12038-008-0065-0 Sievert, 2011, A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt, Liver Int, 31, 61, 10.1111/j.1478-3231.2011.02540.x Chowdhury, 2003, Hepatitis C infection in the general population: a community based study in West Bengal, India, Hepatology, 37, 802, 10.1053/jhep.2003.50157 Sood, 2012, Prevalence of hepatitis C in a selected geographical area of northern India: a population based survey, Indian J Gastroenterol, 31, 132, 10.1007/s12664-012-0251-8 Chadha, 1999, Insignificant prevalence of antibodies to hepatitis C in a rural western area of western Maharashtra, Indian J Gastroenterol, 18, 22 Khaja, 2006, High prevalence of hepatitis C virus infection and genotype distribution among general population, blood donors and risk groups, Infect Genet Evol, 6, 198, 10.1016/j.meegid.2005.04.001 Phukan, 2001, HCV activity in an isolated community in north east India, Indian J Pathol Microbiol, 44, 403 Rao VG. Epidemiology of viral hepatitis in tribal populations of Orissa, Madhya Pradesh/Chattisgarh and Jharkhand. Regional Medical Research Centre for Tribals(RMRTC), Annual Report 2008-2009. EAvailable at: http://icmr.nic.in/annual/2008-09/jabalpur/communicable_diseases.pdf. Chandra, 2003, prevalence, risk factors and genotype distribution of HCV and HBV infection in the tribal population: a community based study in south India, Trop Gastroenterol, 24, 193 Sarkar, 2003, Rapid spread of hepatitis C and needle exchange programme in Kolkata, India, Lancet, 361, 1301, 10.1016/S0140-6736(03)13006-1 Singh, 2000, Hepatitis B, C and human immunodeficiency virus infections in multiple-injected kala azar patients in Delhi, Scand J Infect Dis, 32, 3, 10.1080/00365540050164137 Reid, 2012, Estimating the burden of disease from unsafe injections in India: a cost-benefit assessment of the auto-disable syringe in a country with low blood-borne virus prevalence, Indian J Community Med, 37, 89, 10.4103/0970-0218.96093 Jaiswal, 2002, Prevalence of hepatitis viruses among chronic renal failure patients on haemodialysis in Central India, Dial Transplant, 31, 234 Mittal, 2013, Profile of hepatitis B virus, hepatitis C virus, hepatitis D virus and human immune deficiency virus infection in hemodialysis patients of a tertiary care hospital in Uttarakhand, J Clin Exp Hepatol, 3, 24, 10.1016/j.jceh.2013.02.003 John, 1999, Infections after renal transplantation in India, Transplant Rev, 13, 183, 10.1016/S0955-470X(99)80082-2 Chandra, 2004, Prevalence of hepatitis B and hepatitis C viral infections in Indian patients with chronic renal failure, Intervirology, 47, 374, 10.1159/000080883 Agarwal, 1999, Hepatitis C virus infection during haemodialysis in India, J Assoc Physicians India, 47, 1139 Reddy, 2005, Prevalence of HCV infection in patients on haemodialysis: survey by antibody and core antigen detection, Indian J Med Microbiol, 23, 106, 10.4103/0255-0857.13872 Palainswamy, 2012, Prevalence of HCV, HBV and HIV infections in patients and staff of haemodialysis unit, BMC Infect Dis, 12, P74, 10.1186/1471-2334-12-S1-P74 Jain, 2008, Occult hepatitis C virus infection is more common than hepatitis B infection in maintenance hemodialysis patients, World J Gastroenterol, 14, 2288, 10.3748/wjg.14.2288 Chopra, 2005, Hepatitis C virus infection in haemodialysis patients: “Wolf in Sheep’s clothing”, MJAFI, 61, 241 Verma, 2008, Genotype characterization of hepatitis C virus and its significance in patients with chronic liver disease from Northern India, Diagn Microbiol Infect Dis, 61, 408, 10.1016/j.diagmicrobio.2008.03.011 Amarapurkar, 2001, Prevalence of hepatitis C genotypes in Indian patients and their clinical significance, J Assoc Physicians India, 49, 983 Abraham, 2009, Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease, Indian J Gastroenterol, 28, 53, 10.1007/s12664-009-0018-z Hissar, 2006, Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease, J Med Virol, 78, 452, 10.1002/jmv.20561 Raghuraman, 2003, Distribution of the different genotypes of HCV among patients attending a tertiary care hospital in south India, J Clin Virol, 26, 61, 10.1016/S1386-6532(02)00025-2 Narhari, 2009, Prevalence and geographic distribution of hepatitis C virus genotypes in Indian patient cohort, Infect Genet Evol, 9, 643, 10.1016/j.meegid.2009.04.001 Das, 2002, Geographical distribution of hepatitis C virus genotypes in India, Indian J Pathol Microbiol, 45, 323 Singh, 2004, Distribution of hepatitis C genotypes in patients with chronic hepatitis C infection in India, Indian J Med Res, 119, 145 Chakravarti, 2011, Distribution pattern of HCV genotypes & its association with viral load, Indian J Med Res, 133, 326 Madhavi, 2007, Genotyping of Hepatitis C Virus (HCV) in infected patients from South India, Infect Genet Evol, 7, 724, 10.1016/j.meegid.2007.03.001 Raghuraman, 2004, HCV genotype 4- an emerging threat as a cause of chronic liver disease in Indian (south) patients, J Clin Virol, 31, 253, 10.1016/j.jcv.2004.03.019 Raghuraman, 2005, Hepatitis C virus genotype 6 infection in India, Indian J Gastroenterol, 24, 72 Petta, 2014, Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C, Hepatology, 10.1002/hep.27010 Puri, 2014, INASL-Consensus guidelines for management of HCV in India, J Clin Exp Hepatol, 4 Freshwater, 2008, Inferior response of Asian vs. non-Asian hepatitis C genotype 3 infection to combination antiviral therapy, J Viral Hepat, 15, 115 Pattullo, 2010, Superior response to pegylated interferon and RBV in Asians with chronic hepatitis C, Hepatol Int, 4, 723, 10.1007/s12072-010-9207-1 Manns, 2011, Reduced dose and duration of peginterferon alfa-2b and weight-based RBV in patients with genotype 2 and 3 chronic hepatitis C, J Hepatol, 55, 554, 10.1016/j.jhep.2010.12.024 Sood, 2008, Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with RBV in patients with chronic hepatitis C with genotype 3: an Indian experience, J Gastroenterol Hepatol, 23, 203, 10.1111/j.1440-1746.2007.05057.x Tohra, 2011, Prediction of sustained virological response to combination therapy with pegylated interferon alfa and RBV in patients with genotype 3 chronic hepatitis C, Dig Dis Sci, 56, 2449, 10.1007/s10620-011-1770-3 Acharya, 2012, Treatment of chronic hepatitis due to hepatitis C virus (CH-C) in India: a randomized control trial comparing daily interferon alpha-2b and RBV with daily interferon alpha-2b and glycyrrhizin—a multicentre study, J Clin Exp Hepatol, 2, 10, 10.1016/S0973-6883(12)60079-6 Akbar, 2009, Hepatitis C virus infection: a review of the current and future aspects and concerns in Pakistan, J Gen Mol Virol, 1, 012